AKT1 and acute kidney injury: Advanced studies suggest that ECFCs-sEVs may exert their therapeutic effect in AKI by harboring miR-486–5p, which can inhibit PTEN and activate the AKT pathway, thereby reducing apoptosis in endothelial cells and TECs [114,115].